The cytotoxic efficacy of talazoparib and APE1 inhibitor III were tested alone, combined with decitabine, and combined with each other in primary CD34+ MDS/CMML cells and in primary CD34+ or CD34− AML cells in comparison to healthy CD34+ donor cells. The gene discussed is CD34; the disease is acute myeloid leukemia.